Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial
Authors
Xueshuai Wan (ORCID: https://orcid.org/0000-0003-2140-5384)
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial
Xueshuai Wan, Xiujuan Qu, Yunpeng Liu, Mengyao Zheng et al.
Citations
7 citations
Journal
Gut
Topics
CAR-T cell therapy research
Field-Weighted Citation Impact (FWCI)
7.32
article
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial
Xueshuai Wan, Xiujuan Qu, Yunpeng Liu, Mengyao Zheng, Xiangan Wu, Wei Wu, Xuxu Zhang, Shunda Du, Yuhong Zhou, Karin Wisskirchen, Dongmei Quan, Ulrike Protzer, Wei Li, Ke Zhang, Lu Yang, Xiaorui Wang
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
GutVol. 75(1)
Institutions
Shanghai Medical College of Fudan University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Fudan University (CN), Peking Union Medical College Hospital (CN), Helmholtz Zentrum München (DE), German Center for Infection Research (DE), First Hospital of China Medical University (CN), Shanghai Cell Therapy Research Institute (CN), The Sixth People's Hospital of Shenyang (CN), Cell Medica (Switzerland) (CH), Technical University of Munich (DE), China Medical University (CN)